论文部分内容阅读
目的:观察以左旋氧氟沙星为基础的抗HP治疗的疗效和药物副作用。方法:将54例HP感染患者经常规三联疗法“奥美拉唑+阿莫西林+甲硝唑”治疗失败者分为A组30例和B组24例,对A组给予以左旋氧氟沙星为主的三联补救治疗7天“左氧氟沙星200mg,tid,+耐信(埃索美拉唑镁肠溶片)20mg,qd,+阿莫西林500mg,tid”,B组使用常规四联7天“洛赛克、胶体果胶铋、克拉霉素、甲硝唑四联疗法”补救疗法观察,30天后做呼气试验确定疗效,并作临床对照分析。结果干预组2例失访,余28例完成治疗及随访,其中22例(78.6%)补救根除成功,6例(21.43%)补救治疗失败,9例(32.14%)患者发生轻微不良反应,B组4例(16.67%)失访,4例(20.0%)根除成功,A组与B组进行x2检验,P>0.05。结论含左氧氟沙星的三联方案为安全有效的幽门螺杆菌补救治疗方案。
OBJECTIVE: To observe the curative effect and drug side effects of levofloxacin-based anti-HP therapy. Methods: 54 cases of patients with HP infection by conventional triple therapy “omeprazole + amoxicillin + metronidazole” failed treatment were divided into A group of 30 patients and B group of 24 patients in group A given levofloxacin Star-based triple remedial treatment of 7 days “levofloxacin 200mg, tid, + tolerance (esomeprazole magnesium enteric-coated tablets) 20mg, qd, + amoxicillin 500mg, tid”, B group using conventional quadruple 7 days “Losec, colloidal pectin bismuth, clarithromycin, metronidazole quadruple therapy” remedial therapy observation, 30 days after the breath test to determine the efficacy and clinical control analysis. Results In the intervention group, 2 patients were lost to follow-up. Among them, 28 patients completed treatment and follow-up. Twenty-two patients (78.6%) were successful in eradication therapy, 6 (21.43%) failed to remedial therapy and 9 (32.14% Four patients (16.67%) were lost to follow-up. Four patients (20.0%) were successfully eradicated. Patients in group A and group B received x2 test, P> 0.05. Conclusions The triple regimen with levofloxacin is a safe and effective remedy for Helicobacter pylori.